memantine has been researched along with Nervous System Disorders in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Memantine was administered orally either semiprophylactically, from day 7 postinoculation (PI), or therapeutically, 10 to 11 days PI." | 5.31 | Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. ( Bolton, C; Paul, C, 2002) |
| "Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that was initially indicated for the treatment of moderate to severe Alzheimer's disease." | 2.72 | Memantine and its benefits for cancer, cardiovascular and neurological disorders. ( Abbaszadeh, S; Janssen, PML; Shafiei-Irannejad, V; Soraya, H, 2021) |
| "Kynurenic acid (KYNA) is an antagonist to the α-7nACh and NMDA receptors." | 2.58 | Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement. ( Koola, MM, 2018) |
| "In western countries, Alzheimer's disease (AD) is the most common form of dementia." | 2.43 | The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. ( Lipton, SA, 2005) |
| "Memantine was administered orally either semiprophylactically, from day 7 postinoculation (PI), or therapeutically, 10 to 11 days PI." | 1.31 | Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. ( Bolton, C; Paul, C, 2002) |
| " Dizocilpine was active in this model at a dosage of 1 mg/kg." | 1.28 | Neuroprotective effect of memantine demonstrated in vivo and in vitro. ( Krieglstein, J; Mennel, HD; Peruche, B; Rossberg, C; Seif el Nasr, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Espadinha, M | 1 |
| Viejo, L | 1 |
| Lopes, RMRM | 1 |
| Herrera-Arozamena, C | 1 |
| Molins, E | 1 |
| Dos Santos, DJVA | 1 |
| Gonçalves, L | 1 |
| Rodríguez-Franco, MI | 1 |
| Ríos, CL | 1 |
| Santos, MMM | 1 |
| Shafiei-Irannejad, V | 1 |
| Abbaszadeh, S | 1 |
| Janssen, PML | 1 |
| Soraya, H | 1 |
| Dąbrowska-Bouta, B | 1 |
| Strużyńska, L | 1 |
| Sidoryk-Węgrzynowicz, M | 1 |
| Sulkowski, G | 1 |
| Koola, MM | 1 |
| Ogden, KK | 1 |
| Chen, W | 1 |
| Swanger, SA | 1 |
| McDaniel, MJ | 1 |
| Fan, LZ | 1 |
| Hu, C | 1 |
| Tankovic, A | 1 |
| Kusumoto, H | 1 |
| Kosobucki, GJ | 1 |
| Schulien, AJ | 1 |
| Su, Z | 1 |
| Pecha, J | 1 |
| Bhattacharya, S | 1 |
| Petrovski, S | 1 |
| Cohen, AE | 1 |
| Aizenman, E | 1 |
| Traynelis, SF | 1 |
| Yuan, H | 1 |
| Serrano, F | 1 |
| Deshazer, M | 1 |
| Smith, KD | 1 |
| Ananta, JS | 1 |
| Wilson, LJ | 1 |
| Pautler, RG | 1 |
| Danesh-Meyer, HV | 1 |
| Levin, LA | 1 |
| Lipton, SA | 1 |
| Tilley, JW | 1 |
| Kramer, MJ | 1 |
| Wenk, GL | 2 |
| Danysz, W | 2 |
| Mobley, SL | 2 |
| Schulz, JB | 1 |
| Matthews, RT | 1 |
| Henshaw, DR | 1 |
| Beal, MF | 1 |
| Paul, C | 1 |
| Bolton, C | 1 |
| Seif el Nasr, M | 1 |
| Peruche, B | 1 |
| Rossberg, C | 1 |
| Mennel, HD | 1 |
| Krieglstein, J | 1 |
5 reviews available for memantine and Nervous System Disorders
| Article | Year |
|---|---|
Memantine and its benefits for cancer, cardiovascular and neurological disorders.
Topics: Animals; Cardiovascular Diseases; Excitatory Amino Acid Antagonists; Humans; Inflammation; Memantine | 2021 |
Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
Topics: Animals; Cognitive Dysfunction; Drug Therapy, Combination; Electroconvulsive Therapy; Galantamine; H | 2018 |
Neuroprotection: extrapolating from neurologic diseases to the eye.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Endpoint Determination; Excitatory Amino | 2009 |
The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Topics: Alzheimer Disease; Animals; Excitatory Amino Acid Antagonists; Humans; Memantine; Nervous System Dis | 2005 |
Aminoadamantane derivatives.
Topics: Amantadine; Animals; Antiviral Agents; Humans; Memantine; Nervous System Diseases; Rimantadine | 1981 |
9 other studies available for memantine and Nervous System Disorders
| Article | Year |
|---|---|
Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.
Topics: Blood-Brain Barrier; Cells, Cultured; Dose-Response Relationship, Drug; HEK293 Cells; Hep G2 Cells; | 2020 |
Memantine Modulates Oxidative Stress in the Rat Brain following Experimental Autoimmune Encephalomyelitis.
Topics: Animals; Body Weight; Brain; Encephalomyelitis, Autoimmune, Experimental; Excitatory Amino Acid Anta | 2021 |
Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology.
Topics: Animals; Cells, Cultured; Excitatory Amino Acid Antagonists; Glutamic Acid; HEK293 Cells; Humans; Io | 2017 |
Assessing transneuronal dysfunction utilizing manganese-enhanced MRI (MEMRI).
Topics: Animals; Isoflurane; Magnetic Resonance Imaging; Manganese; Memantine; Mice; Mice, Inbred C57BL; Mic | 2008 |
Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat.
Topics: Acetylcholine; Animals; Basal Ganglia; Behavior, Animal; Cerebral Cortex; Choline O-Acetyltransferas | 1994 |
MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis.
Topics: Amantadine; Animals; Basal Ganglia; Cerebral Cortex; Choline O-Acetyltransferase; Dizocilpine Maleat | 1995 |
Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Anticonvulsants; Coenzymes; Cyclic N-Oxides; Dizocilpine Malea | 1996 |
Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine.
Topics: Animals; Blood-Brain Barrier; Body Weight; Corticosterone; Disease Progression; Encephalomyelitis, A | 2002 |
Neuroprotective effect of memantine demonstrated in vivo and in vitro.
Topics: Adenosine Triphosphate; Animals; Brain Ischemia; Cell Hypoxia; Cells, Cultured; Chick Embryo; Dizoci | 1990 |